The majority of large-scale prospective studies have clearly shown that patients with progressive renal disease require multiple medications, preferably in addition to angiotensin-converting enzyme inhibitors (ACEIs), in order to reach the target blood pressure. [1] [2] [3] Recently, angiotensin II receptor blockers (ARBs) have been proven to possess both antihypertensive and antiproteinuric effects similar to ACE-Is. [4] [5] [6] [7] [8] [9] Of note is that ARBs may be advantageous to ACE-Is in that they have less incidence of coughing and mild influence on serum K concentration. 10 The practical question would then be which combination as an add-on therapy, in addition to either one of the renin angiotensin system (RAS) blockers, would achieve the best outcome. In this communication, we describe a case presentation which supplied some useful data for considering the future strategy of combined treatment for renal disease with hypertension.
The patient was a 40-year-old woman with IgA nephropathy, which had been diagnosed by renal biopsy at a university hospital when she was 20. She was referred to our hospital at the age of 27. At that time, laboratory examinations showed a serum creatinine (Cr) concentration of 61.9 mol/l, Ccr of 110 ml/min and protein excretion of 0.3-0.4 g/day. Due to mild proteinuria, she was followed without medication, and placed on only a low salt diet for about 10 years. However, at the age of 38, mild proteinuria became moderate (1.1-1.2 g/day), and the patient became hypertensive (150/98 mm Hg), necessitating antihypertensive therapy with a long-acting calcium channel blocker (CCB), amlodipine, at 5 mg once a day. As expected, the compliance to the therapy was good, and the CCB effectively lowered her blood pressure from 150/98 mm Hg to 130/80 mm Hg (average of three measurements) within 8 weeks, this level being maintained thereafter. However, as the urinary protein excretion remained unchanged, the ARB candesartan was added at 4 mg once a day with the aim of further reducing the urinary protein excretion. This addition of the ARB to the CCB dramatically decreased the urinary protein excretion from 1.0 ± 0.2 g/ day (mean ± s.d. of three measure- ments) to 0.3 ± 0.1 g/day within 8 weeks, without any change in blood pressure, serum Cr concentration or Ccr. We obtained the patient's informed consent to withdraw the CCB to confirm the additive antiproteinuric effect of the ARB alone. Withdrawal of amlodipine from the combined therapy resulted in a partial return of protein excretion to 0.7 ± 0.2 g/day within 8 weeks ( Figure 1 ). Neither Ccr nor the serum Cr concentration was altered upon comparison with either the combination therapy or the CCB monotherapy. Our findings in this case strongly suggest that combination of an ARB with a CCB has a marked additive effect on protein excretion in some patients with progressive renal disease.
The last two decades have witnessed a tremendous wave of pharmacological development that has yielded numerous antihypertensive agents such as ACE-I, CCB and ARB. Soon after these agents became clinically available, many randomised prospective clinical trials were performed, and these drugs were proved to be effective in reducing blood pressure. Recently, with the overwhelming evidence that earlier and more intensive blood pressure control, preferably SBP less than 130 mm Hg, is required in patients with hypertension, it is clear that these patients are going to require multiple medications to forestall and prevent any cardiovascular complications.
1-3 Along with this trend, a clear general consensus has been established about the usefulness of ACE-Is for retarding the decline in renal function in progressive renal disease. ACE-Is have been shown to have a substantial renoprotective effect independent of systemic blood pressure reduction. 11, 12 Recent clinical studies have also shown that ARBs lower blood pressure as effectively as ACE-Is. ACE-Is and ARBs also equally slow the progression of kidney disease to chronic renal failure. 13, 14 Thus, it should be noted that any combination therapy for progressive renal disease must include either an ACE-I or an ARB. Of note is that ARBs may be more advantageous than ACE-Is when used for patients with impaired renal function, because the resulting increase in serum K concentration is milder with the former than with the latter. 10 Furthermore, ARBs may not result in an abrupt fall in Ccr at first use, whereas this may sometimes happen with ACE-Is. 15 Better compliance due to absence of coughing may also be a benefit of ARBs compared with ACE-Is.
In a clinical trial, Russo et al 5 have reported that combination therapy with an ACE-I and an ARB was better than either agent alone in patients with IgA nephropathy. The evidence was reconfirmed recently by themselves. 16 This may also be the case for type 1 and 2 diabetic nephropathy. 17, 18 However, there are two serious flaws to this add-on combination therapy. One is that the two agents together often have a deleterious effect on hyperkalaemia, owing to excessive suppression of aldosterone production. 19 The other is that the therapy may be associated with deterioration of renal anaemia in patients with impaired renal function. ACE-I-induced deterioration of renal anaemia can be accounted for by the blocking of angiotensin II action, which under normal conditions stimulates erythropoiesis. 20 Therefore, from a practical viewpoint, it seems rational to seek other options besides these two RAS blockers in combination.
Compared with two RAS blockers, simultaneous use of a CCB and an ARB, or a CCB and an ACE-I, seems to be ideal for renoprotection. It is well known that CCBs, per se, are reliable for blood pressure reduction, whereas ARBs or ACE-Is, per se, offer an assured antiproteinuric effect. To date however, little information is available about the efficacy of therapy with a CCB plus an ARB. In our present patient with IgA nephropathy, combination of a CCB with an ARB resulted in marked reduction of proteinuria compared with the use of either agent alone. In fact, the antiproteinuric effect was synergistic rather than merely additive. In the FACET study, diabetic patients were randomised to either an ACE-I or a CCB, and followed. 21 Those not controlled on monotherapy had the other agent added, and this was required in one-third of all patients. Those receiving the combination CCB/ACE-I had the best overall survival rate in the 30 months of therapy. These data suggest that there are at least some patient populations who respond well to combined therapy with a CCB and an ACE-I. CCBs have come under fire in recent years due to their potential for promoting ischaemic events and possible progressive renal dysfunction. 22 However, the use of long-acting CCBs such as amlodipine is unlikely to be associated with the reflux increase in heart rate due to sympathetic nerve activation reported for short-acting CCBs. In fact, a recent study shows that there were no differences in the rates of death from any cause or in the cardiovascular composite end point between the ARB and the CCB. 23 In summary, the present case suggests that therapy with an ARB and a long-acting CCB in combination might have the potential to augment the antiproteinuric effect in patient with progressive renal disease. This combined antihypertensive therapy may be worth trying for patients with any form of progressive renal disease such as diabetic nephropathy who do not respond well to monotherapy. The long-term efficacy of this combination therapy needs to be further addressed in a large-scale prospective clinical study. 
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